DEFA14A filed Mar 20, 2026 at 16:01 ET
Gilead Sciences is holding its 2026 Annual Meeting, where shareholders will vote on several key proposals. The board recommends voting in favor of re-electing all nine director nominees, ratifying Ernst & Young as auditors, approving executive compensation, and amending the equity incentive plan. The board opposes three shareholder proposals requesting an independent board chair, a report on patent exclusivity impacts on patient access, and a report on ESG/DEI compensation metrics.